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ABSTRACT
CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play
an important role in tumor progression. Tested to date CXCR1/2 antagonists and
chemokine-targeted antibodies were reported to affect malignant cells in vitro and
in animal models. Yet, redundancy of chemotactic signals and toxicity hinder further
clinical development of these approaches. In this pre-clinical study we investigated
the capacity of a novel small molecule dual CXCR1/2 inhibitor, Ladarixin (LDX), to
attenuate progression of experimental human melanomas. Our data showed that LDXmediated inhibition of CXCR1/2 abrogated motility and induced apoptosis in cultured
cutaneous and uveal melanoma cells and xenografts independently of the molecular
defects associated with the malignant phenotype. These effects were mediated by
the inhibition of AKT and NF-kB signaling pathways. Moreover, systemic treatment
of melanoma-bearing mice with LDX also polarized intratumoral macrophages to M1
phenotype, abrogated intratumoral de novo angiogenesis and inhibited melanoma
self-renewal. Collectively, these studies outlined the pre-requisites of the successful
CXCR1/2 inhibition on malignant cells and demonstrated multifactorial effects of
Ladarixin on cutaneous and uveal melanomas, suggesting therapeutic utility of LDX
in treatment of various melanoma types.

INTRODUCTION

was also associated with the intratumoral endothelial
cell chemotaxis, neovascularization and angiogenesis in
vitro and in vivo [5]. Up-regulated expression of IL-8 and
CXCL1 were also associated with NF-kB transcription
factor activity in cultured melanoma cells [6, 7]. All of
these observations reinforce the concept that Gro-family
chemokines and CXCL8 (IL-8) act as paracrine and
autocrine mediators on melanoma growth and progression.
The biological effects of these chemokines are mediated
through two G protein-coupled receptors, CXCR1 and
CXCR2 [8]. Engagement of these receptors induces
intracellular signaling transmitted through heterotrimeric
G proteins with Gαi being a predominant G protein
coupled to this receptor family [9]. CXCR1 and CXCR2
receptors also exhibit a markedly distinct ligand binding
pharmacology: CXCR1 is predominantly activated by

Malignant melanoma expresses and secretes
various CXC chemokines, including CXCL1, CXCL2,
CXCL3 (GRO family chemokines) and CXCL8 (IL-8).
These molecules render the tumor microenvironment
and facilitate progression and metastatic dissemination
of melanomas via autocrine and paracrine activation of
CXCR1 and CXCR2 chemokine receptors (reviewed
in [1]). Studies on spontaneously immortal mouse
melanocytes showed that stable expression of GRO
family members enhances colony-forming abilities of
the melanocytes, whereas antibody-mediated blocking
of these chemokines inhibits experimental melanoma
growth [2-4]. Elevated expression of CXCL8 (IL-8)
www.impactjournals.com/oncotarget
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CXCL8 and CXCL6, whereas CXCR2 could be activated
by CXCL1-3 and 5-8 [10]. Expression of both receptors
and multiple ligands by melanoma present certain
challenges in designing therapeutic strategies to attenuate
the effects of these chemokines [11].
To date, several strategies were employed to
reduce/inhibit intracellular signaling mediated by CXCR1
and CXCR2 receptors. A number of ligand-blocking
antibodies and small molecular weight antagonists of these
chemokines, particularly CXCL8, were developed and
tested [11]. Although blocking of individual chemokines
provided certain benefits in treatment of acute and chronic
inflammation [12], this approach may not provide desired
outcome in treating neoplasms due to the redundancy of
chemotactic signals.
Further search for effective competitive antagonists
led to the identification of a number of compounds that can
block CXCR1/2 receptor [11]. An advanced development
program was originated by Dompé Farmaceutici
with Reparixin, the first non-competitive allosteric
CXCR1/2 inhibitor that is currently under active clinical
investigation for the prevention of graft loss in pancreatic
islet transplantation (Phase 3) and treatment of metastatic
triple negative breast cancer (Phase 2). Ladarixin (LDX)
is a second generation dual CXCR1/2 inhibitor due to
its > 100 fold higher affinity for the CXCR2 receptor
and improved pharmacokinetic properties that make
it suitable for oral chronic administration. Ladarixin
inhibits human polymorphonuclear leukocyte (PMN)
migration to CXCL8 (IC50 at 0.7 nM) in vitro, and
prevents PMN infiltration and tissue damage in several
models of IR injury in vivo [13]. LDX is well-tolerated
at all studied doses and showed excellent safety profile in
human subjects in current clinical trials for the treatment
of Type 1 diabetes (unpublished data). In this study, we
demonstrated that LDX attenuates progression of different
melanoma types in vivo via inhibition of cell cycle
progression and motility, blocking of the pro-survival
intracellular signals and induction of apoptosis, alteration
of the intratumoral recruitment of the endothelial cells and
de novo angiogenesis, and hindering of the melanoma selfrenewal mechanisms.

defects for the expression of CXCR1/2 and their ligands
(CXCL1/8). Cutaneous melanoma cells expressing mutant
BRAFV600E(WM164, WM115, WM873) [14, 15], cells
with non-defined molecular defect expressing BRAFG464E
and KRASG12D (C8161) [16] and uveal melanoma cells
harboring an activating mutation in GNAQQ209P (UM001)
[17] were used for this assessment. RT-PCR analysis
showed that CXCL1 and CXCL8 were differently
expressed in the analyzed cells with the overall lowest
expression in WM164 and WM115 and the highest in
WM873-1and in C8161 melanoma cells (Figure 1A).
Secretion of chemokines from these cells and from primary
dark- and light-pigmented primary human melanocytes
(1256b and 1603c, respectively) assessed by chemokine
antibody array showed that levels of CXCR1/2 ligands
were higher in all but one (WM164) melanoma lines as
compared to melanocytes (Figure 1B, 1C). Secretion
of CXCL8 was consistently elevated in all malignant
cells (Figure 1B, 1C). Expression CXCR1/2 receptors
was also examined. RT-PCR and Western Blot analyses
confirmed expression of both receptors in malignant cells
with on average 2 times higher expression of CXCR2
as compared to CXCR1 (Figure 1A). However, FACS
analysis demonstrated that CXCR1 and CXCR2 were not
uniformly present on the surface of the malignant cells.
More than 50% of WM164 and UM001cells have these
receptors consistently present on the cell surface, whereas
only small populations of WM873, C8161and WM115
were recognized as receptor-positive (Figure 1D). FACS
also revealed the existence of a discrete population of the
CXCR1/2 cell surface-positive malignant cells (Figure
1D). These observations were confirmed by the direct
(Figure 1E) and indirect (Supplementary Figure S1A)
immunofluorescent detection of the receptors showing that
WM115 and WM873 cells contained receptor-positive and
negative populations, whereas a majority of the WM164
and UM001 were positive for both receptors on the cell
surface (Figure 1E, Supplementary Figure S1A).

RESULTS

Considering involvement of the CXCR1/2 signaling
in migration, the effect of the LDX on motility of
melanoma cells was examined using in vitro migration/
scratch assay. The presence of LDX in normal culture
media for 24 h led to an inhibition of melanoma cell
motility (Figure 2A, 2B). A more profound inhibition
was observed on cells with higher cell surface CXCR1/2
and lower expression of their ligands (WM164, WM115,
and UM001 lines). Treatment of these cells with LDX
led to 10-fold inhibition of cell migration. Exposure of
WM873 and C8161 cells with lower cell surface receptor
expression to LDX led to a 2-fold decrease of motility
(Figure 2B).

Ladarixin-mediated inhibition of melanoma
motility, adhesion and survival in vitro

Analysis of CXCL1/2/3/8 chemokines and
CXCR1/2 receptors in primary melanoma cells
Considering heterogeneity of human melanomas,
various molecular defects associated with discrete types
of this neoplasm, and variable patterns of chemokine/
receptor expression, we examined several primary human
melanoma cell lines characterized by different molecular
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In these experiments, we observed an increased
number of dislodged cells in the presence of LDX. This
sparked further assessment of cellular attachment and
adhesion by the modified McClay substrata binding assay
as described in our prior studies [18]. The presence of the
LDX during plating and for additional 4 h did not alter the
adhesion of the LDX-treated and control cells, although
a slight reduction in a number of adherent UM001 cells
was observed (Table 1). Exposure of melanoma cells
to LDX for 3 days affected mostly WM164 cells with
3 times more cells remaining on plastic substrata when
cultured in the absence of the LDX. Exposure of cells
to LDX for an additional 2 days had a more detrimental
effect on all cell lines. On average, 3 times more cells
remained attached to plastic substrata when cultured in
the absence of LDX (Table 2). These findings suggest
that LDX-mediated blocking of the CXCR1/2 signaling
affects expression of the adhesion molecules or leads to
the cell death and detachment. Therefore, expression of
cadherins was analyzed by Western blot under referenced
above conditions. High expression of epithelial cadherin
(E-cadherin) was detected only in WM35 melanoma cells
isolated from primary (radial growth phase) lesion. In
cells from more advanced lesions (vertical growth phase
or metastatic), a substantial reduction or absence of this
cadherin was observed (Figure 2C). N-Cadherin, which
is commonly associated with invasion and metastasis of
neoplasms, was detected in all cell lines isolated from local
and distal metastatic lesions with the lowest expression
in the WM35 cell line. P-cadherin, whose expression is
associated with poorly differentiated carcinomas [19, 20],
was barely detectable in all examined cells. Treatment of
cells with LDX did not alter expression of these cadherins
(Figure 2C), suggesting that progressive loss of attached
LDX-treated cells could be attributed to apoptosis. Based
on the in situ cell death detection (TUNEL) assay, on
average, about 3% of all control cells were identified as
apoptotic whereas LDX treatment increased apoptosis up
to 10% for C8161 and WM873 cells, 25 % for WM 164
and WM115 cells, and up to 40% for UM001 (Figure 2D,
2E).
Given that NF-kB supports survival of the
malignant cells via Bcl-2/Bcl-XL-dependent pathway
and augments transcription of CXCR1/2 ligands [1], we
investigated whether LDX treatment abrogates NF-kB
expression and/or activation. To assess whether LDXmediated CXCR1/2 blocking affects NF-kB activity, we
generated several melanoma cell lines stably expressing
NanoLuc® luciferase under the control of the NF-κB
response elements. Exposure of these cells to LDX (1
ηM, 100 ηM, 1µM) for 24 h in vitro led to reduction of
NanoLuc in all examined cells confirming LDX-mediated
down-modulation of the NF-kB activity (Supplementary
Figure S1B). Exposure of all malignant cells to LDX for
72 h led to an intracellular re-distribution of NF-kB and
its accumulation in the cytoplasm. It was particularly
www.impactjournals.com/oncotarget

evident in WM164 and UM001 cells (Figure 2F). Western
Blot analysis with serine536-phosphorylated NF-kBspecific antibodies confirmed the reduction of the NF-kB
activation and nuclear translocation in LDX-treated cells.
It was most prominent in WM35, WM164, WM115, and
UM001, and less pronounced in C8161 cells (Figure 2C).
As Akt plays an important role in controlling the balance
between survival, apoptosis and NF-kB activation [21],
we also assessed the status of this serine-threonine kinase.
Based on the Western Blotting, treatment of the cells with
LDX did not alter the expression of the AKT but markedly
reduced its phosphorylation on Thr308 in all examined
cell lines (Figure 2C). Persistent activation of STAT3
has been shown to mediate several oncogenic features in
many types of cancers, including melanoma [22]. CXCL8
(IL-8) signaling has been implicated in STAT3 activation
and nuclear translocation [23], suggesting that inhibition
of CXCR1/2 may also lead to the inhibition of STAT3
in melanoma cells. However, Western Blot analysis
showed a relatively low basal level of STAT3 expression
in all malignant cells and insignificant changes in STAT3
phosphorylation after LDX treatment(Figure 2C).
Collectively, these in vitro studies demonstrated
that exposure of malignant cells to LDX resulted in
down- modulation of cell cycle progression, motility, Akt
and NF-kB phosphorylation-dependent activation, and
induction of apoptosis independently of molecular defects
underlying tumorigenic phenotype. These studies also
demonstrated that LDX-mediated inhibition of CXCR1/2
has the most profound effect on melanoma cells with
higher level of cell-surface receptors and lower secretion
of ligands (eg. WM164), and only partial effect on cells
with lower number of cell surface receptors and higher
secretion of ligands (eg. C8161).

Ladarixin-mediated inhibition of melanoma
xenografts in vivo
To evaluate the extent of LDX-mediated melanoma
inhibition in vivo and better define the underlying
molecular mechanisms, 4 different human melanoma
cell lines characterized by various levels of cell surface
CXCR1/2, ligands secretion and distinct molecular defects
(WM164V600E,C8161, UM001Q209P and UM004Q209L) were
inoculated into nude athymic mice. Starting from day 10
after inoculation, when lesions reached about 50 mm3
(~4x4x3 mm), experimental groups (n = 10 per group)
were receiving LDX via intraperitoneal (IP) injection
once a day at 15 mg/kg. Control animals were receiving
saline. Consistent with our in vitro studies, systemic
administration of LDX had limited effect on growth of
C8161 melanoma lesions but significantly inhibited
growth of WM164, UM001 and UM004 melanomas
(Figure 3A). All LDX-treated lesions were visually less
vascularized (particularly UM001) compared to untreated
14430
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controls (Figure 3A).
Histological examination showed that all lesions
from LDX-treated animals contained apoptotic regions
with elevated leukocytic infiltrate (Figure 3B). The largest

apoptotic regions occupying on average 2/3 of the entire
tumor volume were detected in LDX-treated C8161
lesions. These regions were characterized by the presence
of TUNEL-positive melanoma cells and a large number

Figure 1: Analysis of chemokines and receptors in primary melanoma cells. A. RT-PCR and Western Blot analyses of CXCL1/8

chemokines and CXCR1/2 receptors expression in different melanoma cell lines (as indicated on the panel). B. Representative images of
the antibody array analysis used for the detection of the secreted chemokine. Blue frame - CXCL1/2/3 (Gro family) chemokines; Green
frame - CXCL1; Red frame - CXCL8. C. Quantitation of chemokines secretion by melanoma cells relative to light-pigmented (1603c)
and dark-pigmented (1256b) melanocytes. Data collected from 3 independent measurements and presented as a fold difference ± SD. Cell
lines are indicated on the panel. D. Analysis of cell-surface CXCR1/2 in melanoma cells by FACS. Cell lines and receptors are indicated
on the histograms. Calculated percentage of receptor-positive cells indicated below the histograms. E. Detection of CXCR1/2 receptors by
fluorescently-labeled receptor-specific antibodies. Red - CXCR1/2 receptors, Blue - DAPI nuclear staining.
www.impactjournals.com/oncotarget
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of CD11b+ leukocytes (Figure 3C, 3D). Considering a
dual role of the tumor-infiltrating CD11b+ macrophages
that may prevent (M1 macrophages) or promote (M2
macrophages) tumorigenesis [24], expression of
nitric oxide synthase 2 (iNOS) as a marker for the M1
macrophages was analyzed. Majority of the intratumoral
CD11b+ cells in control lesions did not express iNOS
(Figure 3C, 3D). On the contrary, more than 60% of
tumor-infiltrating CD11b+ cells in LDX-treated lesions
were iNOS-positive (Figure 3C, 3D).
Considering apoptosis as a primary mechanism
involved in LDX-mediated melanoma cell death, we
examined the status of the key apoptotic markers in
LDX-treated and control lesions. Concurrent detection

of caspase-cleaved PARP and cytokeratin 18 confirmed
apoptotic mechanism of malignant cell death in all LDXtreated animals (Figure 3C, 3D). Quantitation of apoptotic
cells showed that more than 60% of cells in the affected
regions were positive for both apoptotic markers. A
substantial reduction of the proliferating Ki-67+ cells and
increased number of the cleaved cytokeratin 18 (M30+)
cells were also observed in non-apoptotic regions (Figure
3C). Inverse correlation between Ki-67+ proliferating and
M30+ apoptotic cell was most distinct in WM164 treated
melanomas (Figure 3C, 3D). Immunofluorescent detection
of Ki-67 and gp-100 melanoma differentiation antigen
confirmed LDX-mediated inhibition of proliferation in
malignant cell in non-apoptotic tumor regions (Figure 3C).

Figure 2: Analysis of melanoma cell motility and apoptosis. A. Micrographs illustrating LDX-mediated inhibition of melanoma

cell motility assessed by scratch assay. Cell lines and conditions indicated on the micrographs. Scale bar – 100 mm. Introduced scratches are
outlined by puncture lines. B. Quantitation of LDX treated and control melanoma cell migration. Data is presented as an average number
of cells migrated into the scratch (10 independent microscopic fields) ± SD. Statistical significance (p-value) was calculated using 2 tailed
t-test is shown above the columns. Percentage of migrated LDX-treated cells relative to mock-treated control is shown below the columns.
C. Western blot analysis of adhesion and signaling molecules in representative LDX-treated and control melanoma cells (indicated above
the panels). Analyzed molecules are shown to the right of the panels. Phosphorylated NF-kB, STAT3 and AKT are marked as P-proteins.
Beta actin was used as loading control. D. Microscopic analysis of apoptosis in control and LDX-treated melanoma cells by TUNEL
assay. Cell lines, treatment and calculated percentage of apoptotic cells shown on representative images. E. Quantitation of apoptosis as
determined by the TUNEL assay in all investigated melanoma cell lines (indicated below the columns). Data is presented as average of 3
independent experiments ± SD. Five random microscopic fields were used for each treatment condition/cell line to calculate percentage. F.
Indirect immunofluorescent analyses of NF-kB nuclear translocation/activation in control and LDX-treated representative melanoma cells.
Treatment and cell lines are indicated on the panels. Red – Nf-kB, Green – LaminA/C (outlines nuclear membrane).
www.impactjournals.com/oncotarget
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To better define molecular mechanisms involved in
LDX-mediated inhibition of melanoma in vivo, NF-kB and
STAT3 in control and LDX-treated lesions were examined
by the indirect immunofluorescence. This analysis
demonstrated preferential nuclear localization of NF-kB in
the control and cytoplasmic localization in treated lesions

(Figure 4A). Detection of STAT3 in control and LDXtreated lesions did not reveal any significant differences,
although a more pronounced nuclear staining of the STAT3
was detected in controls. These observations were further
confirmed by Western blot analysis. A reduction of the
Ser536-phosphorylated NF-kB and Thr308-phosphorylated

Figure 3: LDX-mediated inhibition of melanoma xenotransplants in vivo. A. Graph of the lesions at 30 days showing tumor

development in LDX-treated and control mice. Data is presented as a mean tumor volume (mm3) ±SD. Statistical significance is presented
as p-value (shown of the graph). B. Representative micrographs of the H&E stained sections of the control and LDX treated lesions
showing the presence of the apoptotic regions (dotted line) and leukocytic infiltrates (black arrows). C. Indirect immunofluorescence-based
characterization of LDX-treated and control tumors. As all mock-treated lesions were similar, micrographs of the control C8161 lesions
are shown as representative controls. Detected antigens are shown to the left of the panels in corresponding colors. Blue - DAPI nuclear
staining. Scale bars: 10 µm (2, 3, and 5th rows from the top) and 100 µm (1, 4th rows from the top). D. Quantitation of antigen-positive cells
shown on panel C. Data is presented as an average percentage of positive cells per microscopic field ± SD.

www.impactjournals.com/oncotarget
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Table 1: Melanoma cell adhesion at plating
Ladarixin

WM164

C8161

TSUM1

Time

Ldx-

0.366±0.085

0.641±0.073

0.126±0.034

4hr

Ldx+

0.288±0.058

0.518±0.063

0.144±0.038

4hr

Ldx-

0.349±0.064

0.521±0.0532

0.394±0.048

3hr

Ldx+

0.221±0.074

0.435±0.034

0.313±0.058

3hr

Ldx-

0.310±0.053

0.524±0.041

0.338±0.069

2hr

Ldx+

0.221±0.051

0.483±0.049

0.322±0.055

2hr

Ldx-

0.333±0.069

0.519±0.061

0.346±0.066

1hr

Ldx+

0.219±0.054

0.418±0.044

0.301±0.034

1hr

Data is presented as optical density measured at 570 nm (OD A570) reflecting attached cells.
Table 2: Assessment of cellular attachment to the plastic substrata (ODA570)
Time
Ladarixin
WM164
C8161
5 Days
LDX 0.178±0.02
0.175±0.012
5 Days
LDX +
0.048±0.017
0.049±0.011
4 Days
LDX 0.192±0.014
0.17±0.014
4 Days
LDX+
0.05±0.013
0.074±0.017
3 Days
LDX 0.199±0.018
0.17±0.012
3 Days
LDX +
0.059±0.012
0.185±0.012

TSUM1
0.156±0.012
0.066±0.013
0.155±0.012
0.081±0.017
0.182±0.013
0.157±0.015

Data is presented as optical density measured at 570 nm (OD A570) reflecting density of the attached cells.
AKT and Tyr705-phosphorylated STAT3 was observed in
all LDX-treated lesions (Figure 4B), suggesting that LDXmediated CXCR1/2 inhibition attenuates NF-kB/AKT
activation making malignant cells susceptible to apoptosis
and reducing their proliferative capacities.
Previous studies demonstrated that CXCR1/2
receptors are expressed by microvascular endothelial
cells and that secretion of CXCR1/2 ligands by
melanoma enhances de novo angiogenesis [25]. Indirect
immunofluorescent detection of the CD31+ intratumoral
blood vasculature demonstrated a drastic reduction
of endothelial cell recruitment and formation of the
intratumoral blood vessels in all examined LDX-treated
lesions. Lack of the intratumoral angiogenesis was
particularly evident in peri-apoptotic regions of the LDXtreated tumors, where blood vessels were not detected
at all (not shown). A reduction CD31+ blood vessels in
non-apoptotic regions of all LDX-treated lesions was
apparent (Figure 4A) and confirmed by the assessment of
microvessel density (Table 3).
Several recent studies suggested that so called
tumor-initiating cells responsible for melanoma selfrenewal display high aldehyde dehydrogenase (ALDH)
activity and enhanced tumorigenicity over ALDH-negative
cells [26, 27] . Considering a potential correlation between
CXCR1/2 expression and ALDH activity reported in
breast carcinoma [28, 29], we tested how LDX treatment

www.impactjournals.com/oncotarget

affects ALDH+ melanoma cells. In all cultured cells,
independently of the tumorigenic mutation, about 4% of
cells were ALDH-positive whereas in xenotransplants it
was increased up to 10% in the lesions (Figure 5A, 5B).
Treatment of tumor-bearing mice with LDX led to an
inhibition of ALDH expression in non-apoptotic regions
of the lesions where ALDH+, HMB45+ (gp100+) malignant
cells were rarely detected (Figure 5A, 5B, 5C). Percentage
of these cells decreased on average 4 times for UM001, 8
times for WM164, and 10 times for C8161 (Figure 5C).
Concurrently, a higher percentage of the ALDH+ cells was
detected in non-proliferating, apoptotic, M30+ regions of
LDX treated lesions (Figure 5B, 5C). In fact, all ALDH+
cells were also positive for caspase-cleaved cytokeratin
18 (Figure 5B). Collectively, these data demonstrated that
treatment of melanoma-bearing mice with LDX leads to
the inhibition of ALDH in non-apoptotic malignant cells
and its induction in cells undergoing apoptosis.

DISCUSSION
Previous studies demonstrated that different CXCR1
and CXCR2 antagonists can block these receptors
inhibiting inflammation and tumor growth in various
animal models. For example, G31P, an IL-8 analog,
was shown to block neutrophil infiltration, pyrexia, and
pulmonary vascular pathology in endotoxemic animals

14434
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[30, 31]. SCH-527123 and SCH-479833, dual CXCR1/2
and CXCR2 antagonists, were shown to inhibit migration
and proliferation of A375SM melanoma cells [32]. SCH527123 was described as a potent inhibitor of CXCR1(IC50 = 41 nM) and CXCR2 (IC50 = 3 nM) mediated
chemotaxis with high affinity [33]. It was shown to
inhibit neutrophil recruitment, mucus production and
goblet cell hyperplasia in animal models of pulmonary
inflammation [34]. The potential therapeutic effect of
SCH-527123 in the treatment of chronic pulmonary
diseases has been widely investigated in several clinical
studies, but the lack of evident long-term clinical benefit
and associated neutropenia led to discontinuation of its

clinical development [35-37]. In this study, we assessed
therapeutic aspects of a novel, dual small molecule
CXCR1/2 inhibitor, Ladarixin, to attenuate development
and progression of human melanomas characterized
by different molecular defects. Ladarixin is orally
bioavailable, potent and selective non-competitive
allosteric CXCR1/2 inhibitor that binds an allosteric
pocket of the trans-membrane region of both receptors.
The allosteric action results in a dramatic reduction of
CXCR1 (IC50 = 0.9 nM) and CXCR2 (IC50 = 0.8 nM)
mediated chemotaxis in the absence of any significant
influence on ligand/receptor binding [38]. Ladarixin
was also effective in decreasing CXCL8-induced

Figure 4: Analysis of NF-kB, STAT3, AKT and angiogenesis in control and LDX-treated lesions. A. Indirect

immunofluorescent analysis of NF-kB, STAT3 and CD31 (as a marker of angiogenesis de novo) in control and LDX-treated lesions. As
all mock-treated lesions were similar, micrographs of the control C8161 lesions are shown as representative controls. Detected antigens
(in corresponding colors) are show to the left of the panels. Blue - DAPI nuclear staining. Cell lines and treatments are shown above the
panels. Scale bar - 10 µm. B. Western blot analysis of NF-kB, STAT3, AKT phosphorylation in control and LDX-treated lesions. Cell lines
and treatments are shown above the panels.
www.impactjournals.com/oncotarget
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polymorphonuclear leukocyte infiltration in several animal
models without a significant dose-related reduction in
systemic neutrophil counts. Confirmation of this last
observation from Phase 1 clinical studies suggests that
allosteric modulation may represent a promising approach
to the design of safe and well-tolerated drugs acting at
chemokine receptors.
Limited number of reports on targeted inhibition of
Gro family chemokines, CXCL8 (IL-8) and their receptors
(CXCR1 and CXCR2) in various tumor models including
melanomas, suggested a potential applicability of these

approaches for tumor growth inhibition (11). However,
redundancy of chemotactic signals presents a significant
challenge in designing therapeutic strategies to attenuate
the effects of CXCR1/2 signaling on melanoma cells
and tumor microenvironments, and the pre-requisites
for the successful treatment remain undefined. Presented
here analysis demonstrated that melanoma cells secrete
different levels CXCL1 and CXCL8 and rather high
levels of CXCL2 and CXCL3 chemokines (Figure
1). Concurrently, tumor cells express both CXCR1/2
receptors. FACS analysis revealed the existence of

Figure 5: Assessment of tumor-initiating ALDH+ melanoma cells in vitro and in vivo. A. Indirect immunofluorescent detection

of ALDH+ melanoma cells in vitro and in vivo. Detected antigens (in corresponding colors) are shown to the right of the panels. Scale
bar - 10 µm. B. Indirect immunofluorescent detection of the ALDH+ cells in non-proliferating (Ki-67-negative), apoptotic (M30-positive)
cells in LDX-treated lesions. Scale bar - 100 µm. C. Quantitation of ALDH+ cells in control cultured cells and non-apoptotic regions of the
LDX-treated lesions (Panel A). Data is presented as average percentage of ALDH+ cells per microscopic field ± SD.
www.impactjournals.com/oncotarget
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Table 3: LDX-mediated inhibition intratumoral microvessel density (MVD)
Cells
MVD (± SD) - // + LDX
% inhibition
t-test
C8161
22±4 // 8±3
62
<0.05
WM164
18±4 // 4±2
78
<0.05
UM001
15±2 // 4±2
73
<0.05
UM004
14±2 // 5±2
65
<0.05
Immunofluorescent staining for microvessel using anti-CD31 was analyzed as described in Materials and Methods. MVD was
quantitated on 10 independent microscopic fields per sample.
distinct populations of receptor-positive and receptornegative cells in otherwise homogeneous malignant cell
cultures (Figure 1D). This analysis also demonstrated
that despite a rather high level of CXCR1/2 expression
in some melanoma cells (eg. WM873 and C8161), only
a small percentage of cells had receptors on the cell
surface, whereas other cells (eg. WM164 and UM001)
had a consistently high number of receptor-positive cells.
These observations suggest that in malignant cells with
high secretion of the autocrine chemokines and high level
of CXCR1/2 expression (as in WM873 and C8161) a
rapid binding and internalization of the ligand/receptor
complexes may lead to the “removal” of the receptors
from the cell surface, as previously observed for CXCR4CXCL12 [39]. These findings also suggest that CXCR1/2
blocking may have limited direct effect on melanoma cells
with the lower number of cell surface receptors and high
levels of autocrine chemokines.
Consistent with the prior data obtained on A375SM
cells using SCH-527123 inhibitor (29), LDX treatment
inhibited melanoma cells motility. However, our analysis
clearly demonstrated that LDX-mediated inhibition
of motility, proliferation, AKT and NF-kB activation
and induction of apoptosis directly correlated with the
percentage of CXCR1/2-positive cells. Thus, WM164,
WM115 and UM001 cells were more susceptible to the
LDX treatment than WM873 or C6181 cell. Importantly,
treatment of different melanoma cells in vitro with 1µM
LDX was more effective than treatment of A37SM with
250 µM SCH-527123 (29).
Consistent with the in vitro data, treatment of the
experimental melanoma-bearing mice with LDX (15 mg/
kg) led to the inhibition of tumor growth independently of
the molecular defects underlying tumorigenic phenotype.
Thus, statistically significant inhibition of BRAFV600E
WM164, GNA11Q209L UM001 and GNAQQ209P UM004
melanomas was observed (Figure 3). These observations
support the notion that malignant cells with higher cellsurface CXCR1/2 expression and lower expression the
ligands (e.g. WM164) are more susceptible to LDX
than cells with lower sell surface receptors (e.g. C8161).
Although, treatment of C8161 melanoma-bearing mice
with LDX did not alter outgrowth of the intradermal
tumors, normalized rate of apoptosis and inhibition of
proliferation were similar in all LDX-treated lesions
(Figure 3D) and C8161 lesions contained large apoptotic
regions approaching 2/3 of the entire tumor volume. Such
www.impactjournals.com/oncotarget

discrepancy could be explained by faster proliferation of
the C8161 cells, higher expression of the CXCR1/2 ligands
that cause rapid internalization of the receptors and higher
microvascular density, particularly, in the periphery of the
established C8161 tumors. Together with the inhibition
of AKT and NF-KB activation/phosphorylation in vitro
(Figure 2) and in vivo (Figure 4A), our data indicate that
LDX-mediated induction of apoptosis in malignant cells
is associated with down-modulation of the AKT/NF-kBmediated pro-survival signals. Comparison of our in vivo
data with previous findings obtained using SCH-527123
at 100 mg/kg dose [32] showed that systemic treatment
of tumor-bearing mice with LDX is more effective, as
reflected by the inhibition of melanoma cell proliferation,
angiogenesis and induction of apoptosis (Figure 3D,
Figure 4).
Moreover, we observed that apoptotic regions in
LDX-treated lesions were heavily infiltrated with CD11b+
TAMs characterized by the uniform expression of the
iNOS, a well-known maker of the M1 macrophages with
tumoricidal activity. These findings suggest that LDX
treatment may directly or indirectly affect polarization
of the TAMs contributing further to the inhibition of the
neoplasms.
Previous studies demonstrated that CXCR1/2
expressed on the surface of the blood endothelial cells play
an important role in the recruitment and the intratumoral
de novo angiogenesis [5, 25]. Our analysis demonstrated a
significant reduction of the intratumoral CD31+ endothelial
cells and blood vessels in LDX-treated tumor-bearing mice
(Figure 4). These findings also indicate that LDX-mediated
alteration of the melanoma-supporting microenvironment
additionally attenuates tumor progression and may further
contribute to the induction of apoptosis of the malignant
cells (eg. C8161).
Presented here studies also support the notion that
LDX treatment prevents “rejuvenation’ of the tumors by
affecting cells with enhanced tumorigenic capabilities,
so called melanoma-initiating cells. Several recent
studies demonstrated that a distinct population of human
melanoma cells with high ALDH activity is responsible
for tumorigenesis and tumor self-renewal [26, 27] and
that silencing of ALDH by shRNA leads to melanoma
cell cycle arrest, apoptosis, decreased cell viability in
vitro and reduced tumorigenesis in vivo [27]. Therefore, a
decrease of the ALDH+ melanoma cells in non-apoptotic
regions of all LDX-treated tumors (Figure 5) could
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be directly related to the reduced tumor-regenerating
capacity and abrogation of melanoma self-renewal
mechanism. Although we identified a higher percentage
of the ALDH+ cells in the apoptotic regions, ALDH
expression coincided with the caspase-mediated cleavage
and release of the cytokeratin18 fragments (Figure 5), the
hallmark of the intermediate stage of apoptosis. Apoptosis
is a tightly regulated process that inevitably leads to
structural and biochemical changes and eventually to cell
death and phagocytosis. Although, ALDH is an enzyme
that detoxifies aldehydic products generated by reactive
oxygen species and enhances cell survival, it is unlikely
that ALDH expression in apoptotic cells may reverse
mid-apoptosis. This notion is indirectly supported by the
accumulation of the macrophages in apoptotic regions that
phagocytose dead melanoma cells.
Collectively, presented here data demonstrate that
Ladarixin, a dual CXCR1/2 small molecule inhibitor,
has a multifactorial effect on melanomas in vitro and in
vivo independently of the genetic defects underlying
tumorigenic phenotype. These effects include inhibition of
melanoma cell motility, NF-kB and AKT-mediated prosurvival signaling, increased apoptosis, down-modulation
of pro-angiogenic signaling and formation of the
intratumoral microvasculature de novo, polarization of the
intratumoral macrophages to M1 tumoricidal phenotype,
and blocking of the ALDH+ cell-dependent melanoma
self-renewal mechanism. These pre-clinical findings
demonstrated therapeutic utility of LDX for the inhibition
of various melanomas independently of the tumor-driving
mutations.

supplements (Thermo/Fisher, Grand Island, NY).

Reagents
Ladarixin, a dual CXCR1 and CXCR2 inhibitor
was provided by Dompé Farmaceutici SpA, Via Campo
di Pile, L’Aquila, Italy. LDX was prepared fresh daily by
dissolving in culture media (in vitro experiments) or in
PBS (in vivo experiments) to desired concentration.

Analysis of chemokines secretion
Chemokine-targeted antibody-based array (Ray
Biotech, Norcross, GA) was used for analysis of
melanocytic cell-derived secreted chemokines as devised
by the manufacturer. Normalization and quantitation of
chemokine secretion was done using array-specific Ray
Biotech Analysis Tool.

FACS
Fluorescently-labeled CXCR1 and CXCR2-specific
antibodies for FACS were from BioLegend (San Diego,
CA). Cell sorting was done on Guava EasyCyte system
and analyzed using InSyte Software (Millipore, Billerica
MA).

In vitro migration assay
Cells were plated at sub-confluent density onto
6-well plates and grown to confluence. Then, a 0.5 mm
scratch was introduced and cells were allowed to migrate
into the area for 24 h in the presence or absence of LDX
(1x10-5 M). Ten independent images were taken from each
cell line/condition and cells migrated into the scratch,
were enumerated.

MATERIALS AND METHODS
Cell lines and culture
All WM and C8161 primary melanoma cell lines
were kindly provided by Dr. M.Herlin (Wistar Institute,
Philadelphia PA). Cell were cultured in MCDB164/L15
media (4/1) supplemented with 2% Fetal Bovine Serum
(FBS), Bovine insulin, and calcium chloride. Uveal
melanoma lines UM001 and UM004 characterized by
the activating mutations in GNAQQ209P and GNA11Q209L
were provided by Dr. T. Sato (Thomas Jefferson
University, Philadelphia PA) and cultured in RPMI1640
media supplemented with 10% FBS, β-mercaptoethanol,
penicillin and streptomycin. Derivative melanoma cell
lines expressing Nano luciferase under the control of
the NF-kB response elements were generated by stable
transfection of the parental cells with pNL3.2 NF-kBRE [NlucP NF-kB-RE Hygro] (Promega, Madison, WI).
Primary human melanocytes were kindly provided by Dr.
Z. Abdel-Malek (University of Cincinnati, Cincinnati,
OH) and cultured in Epilife culture media with TPA-free
www.impactjournals.com/oncotarget

Melanoma cell adhesion and attachment
Different melanoma cells were plated onto 96 well
plates and allow attaching to plastic substrata for 1, 2, 3
and 4 h or kept up to 5 days in the presence or absence of
LDX (1x10-5 M) in culture media. At indicated time points,
cells were fixed in 3% formaldehyde and stained with
0.1% crystal violet. After washes, plates were scanned
at 570 nm on Bio Tech FL600 plate reader (Biotech
Inc., Richmond, VA). Results were obtained from three
independent experiments, three wells for each experiment.

Assessment of apoptosis
Apoptosis was assessed using In Situ Cell Death
detection kit (TUNEL assay) (Roche Bioscience,
14438
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Quantitation of microvessel density (MVD)

Indianapolis, IN). Quantitation was done on images of 5
random microscopic fields per cell line per treatment.

Individual sections of LDX-treated and untreated
tumor lesions were stained with CD31-specific antibodies
(Thermo/Fisher, Grand Island, NY). Microvessel density
was determined on ten random hotspots by direct counting
of CD31-positive blood vessels as described previously
[41]. Percent inhibition Thermo/Fisher, Grand Island, NY
between MVD of untreated and treated lesions. MVD
was assessed in control and LDX-treated lesions of a
compatible size.

Treatment with LDX in vitro and in vivo
For all in vitro experiments, unless otherwise
stated, LDX was dissolved in phosphate buffered saline
(PBS), filter-sterilized and used at 1x10-5 M. For in vivo
treatment of tumor-bearing animals, LDX was dissolved
in PBS, filter-sterilized and used at 15 mg/kg. LDX was
administered via intraperitoneal (IP) injection once a day,
every day, for the duration of the experiment. The dose
was abopted from prior experiments on the 1st generation
of CXCR1 inhibitor, Reparixin [40]

RT-PCR
Total RNA was isolated from cultured melanoma
cells using RNeasy total RNA extraction kit (Qiagen,
Valencia, CA). First-strand DNA was synthesized
using Super Script III reverse transcriptase (Invitrogen,
Grand Island, NY). Chemokines and receptors were
amplified using the following primers: CXCL1 forward
5’- AGGGAATTCACCCCAAGAAC-3’ and reverse
5’- TGGATTTGTCACTGTTCAGCA -3’; CXCL8
forward 5’-ATGACTTCCAAGCTGGCC-3’ and reverse
5’-CAGACAGAGCTCTCTTCC-3’; CXCR1 forward 5’AGGGGCCACACCAACCTTCTG -3’ and reverse 5’AGTGCCTGCCTCAATGTCTCCA 3’; CXCR2 forward
5’- CAGTTACAGCTCTACCCTGCC -3’ and reverse
5’-CCAGGAGCAAGGACAGACCCC- 3’. Amplification
of β-Actin was used as a loading control.

Animal treatment
Eight cohorts of NCrNU-M nude spontaneous
mutant standard athymic mice (Taconic, Hudson, NY) (n
= 10 per cohort) were intradermally injected with 1x106
melanoma cells (WM164, C8161, UM001, UM004) into
right flanks in 30µl of saline. Lesions were pre-established
for 10 days. Then, experimental animal were treated via
IP injection of 100 l of LDX in saline at 15 mg/kg dose,
whereas 3 cohorts of control mice received saline. Dose
and rout of administration were adopted from prior in vivo
studies with first generation CXCR1 inhibitor, Reparixin
[40].

Tumor measurements

Quantitation of immunostainings

Progression of the intradermal lesions was
monitored by measuring 3 longest diameters using digital
calipers. Tumor volume was calculated by multiplication
of width x length x height.

To quantify cells detected in lesions by the
indirect immunofluorescence, 5 consecutive 7 µm cryosections were taken from individual samples with 100
µm intervals. All generated sections were stained with
respective antibodies and images of 3 random microscopic
fields were taken. Fluorescent antibody-labeled cells were
quantified on images using ImagePro software. Data for
each antigen was averaged and standard deviations were
determined.

Indirect immunofluorescent and Western blot
analyses
Indirect immunofluorescent detection of antigens
was done on paraformaldehyde fixed, Triton X-100
permeabilized 7 µm cryo-sections or on cells plated onto
glass chamber slides (Millipore, Billerica, MA) according
to standard protocol. After permeabilization, slides were
washed in PBS, blocked with 1% BSA and incubated with
primary and secondary antibodies for 1 h each following
counterstaining of nuclei with DAPI (Sigma, St. Louis,
MO). Species-specific AlexaFluor488- or AlexaFluor594 labeled secondary antibodies were from Thermo-Fisher
(Thermo/Fisher, Grand Island, NY). Western blot analysis
was done using cell and tumor lysates in RIPA buffer. All
antibodies were used in recommended dilutions (provided
in Supplementary Materials and Methods).

www.impactjournals.com/oncotarget

Statistical analysis
Comparison of two samples (control vs treatment)
was done using paired 2-tailed t-test. In tumor growth
experiments, difference between LDX-treated and control
tumors was considered statistically significant when
significant difference was observed at 3 consecutive time
points. p < 0.05 was considered statistically significant.
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